Earnings
Cabaletta Bio Has $299.4 Million To Carry Its Treatment Program Into 2028, Company Says
Research spending rose to $47.1 million as Cabaletta targets a myositis approval application in the first quarter of 2028.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Research spending rose to $47.1 million as Cabaletta targets a myositis approval application in the first quarter of 2028.
Earnings
The completed Lee sale brought in $698 million, helping fund planned share repurchases as Wrangler and Helly Hansen grow.
Earnings
Vector powered advertising growth, while Unity forecasts a further jump in the businesses it is prioritizing.
SEC Filings
The battery maker eliminated approximately 220 positions and is investing $19 million to double South Korean drone battery capacity.
SEC Filings
The quarterly loss widened to $193.6 million, with manufacturing, late-stage trials and launch preparations driving higher costs.
SEC Filings
The drugmaker also lifted its 2030 revenue outlook to more than $1 billion, from approximately $750 million.
SEC Filings
The organ-transplant technology company raised its annual sales outlook as liver and heart volumes grew and logistics added revenue.
Earnings
The drug developer expects its $202.9 million cash pool to fund operations into the second quarter of 2028.
SEC Filings
Customer contracts reached $20.3 billion, while IREN targets another $6 billion in funding for its planned expansion.
SEC Filings
Lower administrative costs helped the drug developer, which expects initial Duchenne muscular dystrophy trial data in 2027.
SEC Filings
Eton intends to test faster-release formulations in 2027 after preliminary results from a four-week study in healthy volunteers.
SEC Filings
Testing volumes rose 24%, but sales-team shortfalls, seasonal ordering and delayed development projects held growth below management’s expectations.